We are not going to rank cat's claw brands, and we would be sceptical of anyone who does. The documentation in this category is too thin and too inconsistent to support a numbered list, and a ranking published today would be out of date the next time a brand changes contract manufacturer without telling anyone. What we can give you is the framework we actually use as a distributor — nine checks, in the order we run them, applied to the paperwork rather than to the marketing.
Botanical Blends does not manufacture, formulate or private-label anything. We carry other companies' brands. That means our entire job is document review and supplier diligence, and it means the framework below is not theoretical: it is the checklist that decides what goes on our shelf and what does not.
The nine checks, in order
| # | Check | Fails if |
|---|---|---|
| 1 | Is a certificate published? | “Available on request,” or a COA button with no file behind it |
| 2 | Is it traceable to your pack? | No batch code, lot “N/A,” or a sample name that is not the product |
| 3 | What analytes are on the panel? | The compounds that matter are simply absent from the list |
| 4 | Is the method accredited? | Footnotes exclude the method carrying the result you care about |
| 5 | Is there a purity panel? | Heavy metals, microbials and solvents marked “NT” |
| 6 | Does the certificate corroborate the label? | Total alkaloids 0.00 on a product sold as a botanical extract |
| 7 | What else does the brand's house sell? | A scheduled-compound SKU under the same or a sibling name |
| 8 | Does the label arithmetic reconcile? | Stated ingredient totals exceed the measured tablet weight |
| 9 | Is the company traceable? | No corporate registration, no facility registration, no contact |
1. Published, not “available on request”
Request-only is not publication. Neither is a badge reading “3rd Party Tested,” nor a line of text reading “COA Link” with no URL behind it — we have found both, live, on real retail pages in this category. The test is simple: can you download a PDF right now, without emailing anyone? If not, treat the testing claim as unsupported.
2. Traceable to the pack in your hand
A certificate is a statement about one batch on one day. It is only useful if you can connect it to what you bought. Look for a batch or lot number, a sample identifier, a receipt date and an analysis date, a digital signature, and a product name that matches the SKU. One well-circulated certificate in this category carries the sample name “Unknown tablets” and lot number “N/A.” It is a real document from a real lab, and it is untraceable to any specific product.
Also check the date. A certificate from eighteen months ago tells you about a batch that is long gone. The mechanics are in how to read a COA.
3. Analyte coverage — the check almost nobody runs
This is the single most important item on the list, and it is the one the category is quietest about.
A laboratory panel reports on the compounds it was asked to look for. Nothing else. A page of “ND” results looks reassuring in a way that has very little to do with how much ground the panel actually covers.
We will be specific about our own situation, because generalities are cheap. The supplier certificates we hold cover, and report non-detect for: 7-hydroxymitragynine, mitragynine, speciociliatine, speciogynine, paynantheine, corynantheidine and mitraphylline. Those results are what allow us to say “no kratom,” “no mitragynine” and “no 7-OH,” and those three statements are the only ones we make, because they are the only ones substantiated.
Those certificates do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B. So we do not claim clearance on them, and neither should anyone else quoting the same documents. A certificate cannot exonerate a compound it never looked for. The DEA's second Notice of Intent, published in the Federal Register on July 6, 2026 as FR Doc 2026-13581, names mitragynine pseudoindoxyl, MGM-15 and MGM-16 with no threshold — any detectable amount. That is precisely the gap most panels in this market leave open, and closing it takes a new panel, not a better summary line.
One correction to a common line of criticism, since accuracy cuts both ways: the objection here is coverage, not sensitivity. A detection limit of 120.5 parts per million sounds alarming until you do the arithmetic — that is 0.1205 mg per gram, so on a three-gram chew the undetected ceiling is roughly 0.36 mg. The instruments are not the weak point. The analyte list is.
4. Accreditation scope, which is per method and not per laboratory
ISO/IEC 17025 accreditation is granted for specific methods within a defined scope. It is never a blanket property of a lab, and a certificate can carry both accredited and non-accredited results on the same page.
Read the footnotes. On one cat's claw certificate we reviewed in full, an entire method group is footnoted as validated by the laboratory but not by the accrediting body, and therefore not an accredited work item. The lab holds genuine accreditation. It simply does not extend to every method on the page. We walk through that document in our review of BLACK cat's claw.
5. Purity, not just actives
An alkaloid panel is half a certificate. The other half is heavy metals (arsenic, cadmium, lead, mercury), microbials, mycotoxins, pesticides and residual solvents. For a bark extract from the Amazon basin, heavy metals are not a formality — plants accumulate what is in their soil.
Here is where the category confounds expectations. Some products with the narrowest alkaloid panels carry the broadest purity panels, and at least one product with an unusually informative alkaloid panel has every purity line marked “NT — not tested” with method dates listed as “TBD.” A brand is rarely uniformly good or uniformly bad. Score the checks separately.
6. Does the certificate corroborate the label?
A cat's claw product should contain measurable Uncaria tomentosa material, and there are marker compounds that show it: mitraphylline, rhynchophylline, isorhynchophylline and related oxindole alkaloids.
We will apply this one to ourselves first. Both of the incumbent certificates behind products in our own category report Total Alkaloids 0.00 and mitraphylline non-detect. That does not corroborate a claim that the product contains a proprietary Uncaria alkaloid — so we removed that sentence from our storefront rather than leave it running on brand marketing. You may still see language of that kind on brand listings; where a brand makes the claim, it is the brand's claim to substantiate, and it should be attributed to the brand rather than repeated as fact by a retailer.
By contrast, one brand in the category publishes a certificate reporting isorhynchophylline at 0.28 percent, quantified at 2.82 mg per gram. On that brand's own documentation, that is an affirmative composition result, and it is rare enough in this market to be a genuine point of comparison. If you want the botanical background, see what is cat's claw.
7. Brand lineage — look at the whole house, not the one SKU
This check has no equivalent in ordinary supplement shopping, and in this category it is decisive.
Many cat's claw brands are operated by companies that also sell 7-OH, mitragynine or MGM products under adjacent names, sometimes from the same warehouse and occasionally with certificates hosted on the same page. A one-character brand-name difference between a botanical SKU and a scheduled-compound SKU is a real pattern, not a hypothetical. So is the reverse-engineering tell: a 7-OH house launching a cat's claw line weeks before a scheduling date. What happens to those houses is the subject of what happens to 7-OH brands.
Shared lines create shared risk. If a manufacturer runs both product types, cross-contamination is a physical possibility that only segregated manufacturing and independent testing can answer. Ask two questions in writing: who manufactures this, and what else runs on that line?
A related trap: white-label duplication. We have found the same formula at identical specification — three scored tablets, identical six-ingredient deck, only the flavour names differing — selling under three separate brand names at three different prices, with one retailer serving pages for one brand from another brand's URL handles. Stocking two of them looks like variety and is actually one product. Identical spec plus identical ingredient deck plus no disclosed manufacturer equals one product.
8. Does the arithmetic work?
Add up the ingredient panel and compare it with the tablet. One published deck in this category sums to 720 mg per stated half-tablet serving — 1,440 mg per tablet — against a measured unit weight of 780.9 mg on the brand's own certificate. That is physically impossible, and the most likely cause is a per-tablet figure mislabelled as per-serving. Benign or not, it is a live label-accuracy defect that any retailer copying channel copy inherits word for word.
The same scepticism applies to the headline milligram number. “600mg” on a cat's claw pack normally means three 200 mg tablets, and the 200 mg normally refers to a proprietary blend declared on the brand's label, not to any isolated compound. Comparing a 600 mg pack against a 150 mg tablet against a 1,000 mg shot is comparing three different measurements of three different things. Milligram totals are not a strength ranking, and treating them as one is how this category gets sold.
9. Is there a company behind it?
Look for a corporate site, a state business registration, an FDA food-facility registration, a named manufacturer and a way to reach someone. Several brands with genuine multi-retailer distribution in this category have none of these. If something goes wrong with a batch, an untraceable counterparty is who you will be trying to contact.
The 2026 context you should factor in
Two DEA Notices of Intent under 21 U.S.C. 811(h) were published in the Federal Register on July 6, 2026. FR Doc 2026-13580 covers 7-hydroxymitragynine above a threshold of 0.050% w/w or 1.00 mg per article. FR Doc 2026-13581 covers mitragynine pseudoindoxyl, MGM-15 and MGM-16 with no threshold at all. The orders take effect on or after August 5, 2026, on the date the order publishes, and run two years with a possible one-year extension. Under 21 U.S.C. 811(h), a temporary scheduling order of this kind is not subject to judicial review.
There is no grace period and no sell-through. That has a direct effect on brand comparison: expect new cat's claw lines to appear rapidly, launched by houses whose existing portfolios are about to become unsellable. A brand with no history is not automatically worse than one with a bad history — but a brand launched days before a scheduling deadline by a company whose other products are being scheduled deserves the whole nine-point treatment, not a shortcut. See is 7-OH banned and the 7-OH threshold explained.
Frequently Asked Questions
Which cat's claw brand is best?
We do not answer that question, because the honest answer depends on which of the nine checks matters most to you and because the answer changes with each batch. Run the checks on the specific pack you are considering. What we hold is published on our certificate of analysis page, gaps included.
Is a higher milligram number a stronger product?
No. The figure usually describes a proprietary blend total declared on the brand's label, and different brands measure per tablet, per serving or per pack without saying which. Two products advertising the same number can contain entirely different material.
Can a brand say its cat's claw product is clear of the newly scheduled compounds?
Only for the compounds its certificate actually tests for, on the batch in front of you. Most panels in this market do not include mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B — ours do not — and where a panel omits a compound, no claim about that compound is supported, by us or by anyone else. Treat a broad reassurance as a reason to go and read the analyte list.
Is cat's claw affected by the DEA scheduling action?
Cat's claw is Uncaria tomentosa, a different plant from kratom (Mitragyna speciosa), and it is not named in either notice. The risk is not that the plant is covered; it is that a product sold as cat's claw might contain something that is. That is why the analyte-coverage check exists. See cat's claw versus kratom versus 7-OH.
What do you do when a brand you carry fails one of these checks?
We say so, publicly, and we change the copy or the shelf rather than the standard. That is what happened with the composition sentence described under check six. You can see what we currently stock in the cat's claw collection, and wholesale buyers can run the same framework on our documentation via our wholesale page.
These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use. Legality depends on the specific product and applicable state law — check the rules where you live. Nothing here is legal advice.